In a study reported yesterday in JAMA Internal Medicine, children and adolescents previously diagnosed with multisystem inflammatory syndrome (MIS-C) reported no serious complications after COVID-19 vaccination. Almost all participants received the Pfizer COVID-19 vaccine. The Centers for Disease Control and Prevention recommends COVID-19 vaccination for patients with a history of MIS-C, a rare and potentially fatal immune reaction to SARS-CoV-2 infection. According to CDC data, over 9,000 U.S. patients have been diagnosed with MIS-C, which appears to be on the decline.
 
“A big part of that decline is that COVID vaccination has been protective against this rare condition in those who have received it,” said Audrey Dionne, M.D., a pediatric cardiologist at Boston Children’s Hospital who served as co-leader for the study, funded by the National Institutes of Health.

Related News Articles

Headline
The Occupational Safety and Health Administration June 30 released a proposed rule to remove what remains of its emergency temporary standard for occupational…
Headline
The latest video in the AHA’s series “Medicaid: Real Lives, Real Care” features Melissa Fannon-Wisner, DNP, nurse educator and nurse practitioner at Valley…
Headline
Kevin McEwan, DNP, R.N., chief nursing officer at Madison Memorial Hospital, shares how Medicaid provides vital behavioral health and maternal and child care…
Headline
The Alliance for Innovation on Maternal Health, with support from the Health Resources and Services Administration, will host a five-part learning series…
Blog
Even before the COVID pandemic, the mental health and wellness of our young people was failing. The pandemic exacerbated the crisis and made it difficult for…
Headline
Department of Health and Human Services Secretary Robert F. Kennedy Jr. May 27 announced in a post on X that the Centers for Disease Control and Prevention…